AR101116A1 - Formas de dosificación farmacéuticas para administración oral - Google Patents
Formas de dosificación farmacéuticas para administración oralInfo
- Publication number
- AR101116A1 AR101116A1 ARP150102160A ARP150102160A AR101116A1 AR 101116 A1 AR101116 A1 AR 101116A1 AR P150102160 A ARP150102160 A AR P150102160A AR P150102160 A ARP150102160 A AR P150102160A AR 101116 A1 AR101116 A1 AR 101116A1
- Authority
- AR
- Argentina
- Prior art keywords
- weight
- pharmaceutical dosage
- dosage form
- drug
- microcrystalline cellulose
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 5
- 239000003814 drug Substances 0.000 abstract 5
- 229940079593 drug Drugs 0.000 abstract 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 5
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 5
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- USUZGMWDZDXMDG-CYBMUJFWSA-N 4-[(5r)-6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile Chemical compound FC1=CC(C#N)=CC=C1[C@@H]1N2C=NC=C2CC1 USUZGMWDZDXMDG-CYBMUJFWSA-N 0.000 abstract 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 3
- 239000000314 lubricant Substances 0.000 abstract 3
- 239000000463 material Substances 0.000 abstract 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 2
- 229930195725 Mannitol Natural products 0.000 abstract 2
- 239000004615 ingredient Substances 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 239000000594 mannitol Substances 0.000 abstract 2
- 235000010355 mannitol Nutrition 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- -1 mono-phosphate salt Chemical class 0.000 abstract 2
- 229920002785 Croscarmellose sodium Polymers 0.000 abstract 1
- 208000014311 Cushing syndrome Diseases 0.000 abstract 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 abstract 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 abstract 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 abstract 1
- 229960001681 croscarmellose sodium Drugs 0.000 abstract 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 abstract 1
- 238000007908 dry granulation Methods 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 abstract 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 abstract 1
- 238000009490 roller compaction Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000377 silicon dioxide Substances 0.000 abstract 1
- 235000012239 silicon dioxide Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/2036—Silicones; Polysiloxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicación 1: Una forma de dosificación farmacéutica para administración oral que comprende (a) el fármaco 4-[(5R)-6,7-dihidro-5H-pirrolo[1,2-c]imidazol-5-il]-3-fluorobenzonitrilo como se define por la fórmula [1] o cualquier sal farmacéuticamente aceptable del mismo, y (b) al menos 30% por peso de celulosa microcristalina con base en el peso total de dicha forma de dosificación farmacéutica. Reivindicación 3: La forma de dosificación farmacéutica según cualquiera de las reivindicaciones anteriores, en donde dicho fármaco está presente como sal de fosfato, preferiblemente como sal de mono-fosfato. Reivindicación 11: La forma de dosificación farmacéutica según cualquiera de las reivindicaciones anteriores que comprende: (a) 4 ± 1%, calculado con base a su base libre, por peso del fármaco 4-[(5R)-6,7-dihidro-5H-pirrolo[1,2-c]imidazol-5-il]-3-fluorobenzonitrilo presente como sal de monofosfato, (b) 77 ± 7% por peso de la celulosa microcristalina, (c) 0.6 ± 0.2% por peso de dióxido de silicio coloidal, (b) 10 ± 2% por peso de manitol, y opcionalmente que comprende además: (e) 2 ± 0.5% por peso de un agente disgregante, preferiblemente croscarmelosa de sodio, y (f) 1.5 ± 0.5%, por peso de un lubricante, preferiblemente estearato de magnesio con base en el peso total de dicha forma de dosificación farmacéutica. Reivindicación 15: El proceso según las reivindicaciones 12 a 14 caracterizado además por los siguientes pasos del proceso: (1) mezclar el fármaco junto con la celulosa microcristalina y opcionalmente ingredientes adicionales tales como un agente deslizante, un agente disgregante. y un agente lubricante, para obtener una mezcla compactable por máquina, (2) compactar la mezcla compactable por máquina mediante granulación en seco, preferiblemente mediante compactación con rodillo, para obtener un material compactado, (3) mezclar el material compactado con dióxido de silicio coloidal, y opcionalmente con ingredientes adicionales tales como celulosa microcristalina, manitol, un agente disgregante, y un lubricante, para obtener una mezcla comprensible por máquina, (4) comprimir la mezcla comprensible por máquina mediante el uso de una máquina de formación de comprimidos para obtener los comprimidos. Reivindicación 17: El uso de celulosa microcristalina para transformar el fármaco 4-[(5R)-6,7-dihidro-5H-pirrolo[1,2-c]imidazol-5 il]-3-fluorobenzonitrilo en un material farmacéuticamente procesable. Reivindicación 18: Una forma de dosificación farmacéutica según cualquiera de las reivindicaciones 1 - 11 o la reivindicación 16 para uso en el tratamiento de la enfermedad de Cushing o síndrome de Cushing.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462021271P | 2014-07-07 | 2014-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR101116A1 true AR101116A1 (es) | 2016-11-23 |
Family
ID=53610933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150102160A AR101116A1 (es) | 2014-07-07 | 2015-07-06 | Formas de dosificación farmacéuticas para administración oral |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US10143680B2 (es) |
| EP (2) | EP3166596B1 (es) |
| JP (2) | JP6731136B2 (es) |
| KR (1) | KR102468610B1 (es) |
| CN (1) | CN106470704B (es) |
| AR (1) | AR101116A1 (es) |
| AU (1) | AU2015287336B2 (es) |
| BR (1) | BR112016030243B1 (es) |
| CA (1) | CA2954393C (es) |
| CL (1) | CL2017000026A1 (es) |
| CY (1) | CY1120749T1 (es) |
| DK (1) | DK3166596T3 (es) |
| EA (2) | EA033685B1 (es) |
| EC (1) | ECSP17008187A (es) |
| ES (1) | ES2686704T3 (es) |
| HR (1) | HRP20181406T1 (es) |
| HU (1) | HUE039037T2 (es) |
| IL (1) | IL249374B (es) |
| LT (1) | LT3166596T (es) |
| MX (1) | MX2016017315A (es) |
| PE (1) | PE20170201A1 (es) |
| PH (1) | PH12016502540B1 (es) |
| PL (1) | PL3166596T3 (es) |
| PT (1) | PT3166596T (es) |
| SG (1) | SG11201610227TA (es) |
| SI (1) | SI3166596T1 (es) |
| TN (1) | TN2016000557A1 (es) |
| TW (1) | TWI707682B (es) |
| WO (1) | WO2016005880A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL301471B2 (en) | 2016-10-27 | 2025-02-01 | Damian Pharma Ag | Aldosterone synthase inhibitor |
| SG11202010906XA (en) | 2018-05-03 | 2020-12-30 | Damian Pharma Ag | R-fadrozole for use in the treatment of aldostonerism |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070191487A1 (en) | 2004-03-17 | 2007-08-16 | Rigassi-Dietrich Petra G | Galenic formulations of organic compounds |
| GT200600381A (es) * | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| CA2680684A1 (en) * | 2007-03-13 | 2008-09-25 | Takeda Pharmaceutical Company Limited | Solid preparation comprising 2-[[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1 (2h)-pyrimidinyl]methyl]-4-fluorobenzonitrile |
| LT2523731T (lt) * | 2010-01-14 | 2019-02-11 | Novartis Ag | Antinksčių hormoną modifikuojančio agento panaudojimas |
| US20120064157A1 (en) * | 2010-08-27 | 2012-03-15 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| DK2753312T3 (da) * | 2011-09-08 | 2017-02-13 | Mereo Biopharma 2 Ltd | Anvendelse af en aromatase-inhibitor i behandlingen af hypogonadisme og relaterede sygdomme |
| PE20142358A1 (es) * | 2012-01-17 | 2015-01-30 | Novartis Ag | Nuevas formas y sales de un dihidropirrolo[1,2-c]imidazolilo, inhibidor de la aldosterona sintasa o aromatasa |
| WO2013126326A1 (en) | 2012-02-21 | 2013-08-29 | Celgene Corporation | Solid forms of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, compositions and methods of use thereof |
| AU2013246908B2 (en) * | 2012-04-12 | 2016-06-30 | Novartis Ag | Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors |
| EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
-
2015
- 2015-07-06 HU HUE15738484A patent/HUE039037T2/hu unknown
- 2015-07-06 US US15/323,991 patent/US10143680B2/en active Active
- 2015-07-06 JP JP2017500904A patent/JP6731136B2/ja active Active
- 2015-07-06 HR HRP20181406TT patent/HRP20181406T1/hr unknown
- 2015-07-06 MX MX2016017315A patent/MX2016017315A/es active IP Right Grant
- 2015-07-06 AU AU2015287336A patent/AU2015287336B2/en active Active
- 2015-07-06 DK DK15738484.3T patent/DK3166596T3/en active
- 2015-07-06 SI SI201530377T patent/SI3166596T1/sl unknown
- 2015-07-06 EP EP15738484.3A patent/EP3166596B1/en active Active
- 2015-07-06 CN CN201580036746.0A patent/CN106470704B/zh active Active
- 2015-07-06 ES ES15738484.3T patent/ES2686704T3/es active Active
- 2015-07-06 CA CA2954393A patent/CA2954393C/en active Active
- 2015-07-06 WO PCT/IB2015/055098 patent/WO2016005880A1/en not_active Ceased
- 2015-07-06 TW TW104121894A patent/TWI707682B/zh active
- 2015-07-06 EA EA201790140A patent/EA033685B1/ru not_active IP Right Cessation
- 2015-07-06 PE PE2016002812A patent/PE20170201A1/es not_active Application Discontinuation
- 2015-07-06 TN TN2016000557A patent/TN2016000557A1/en unknown
- 2015-07-06 AR ARP150102160A patent/AR101116A1/es not_active Application Discontinuation
- 2015-07-06 PT PT15738484T patent/PT3166596T/pt unknown
- 2015-07-06 PL PL15738484T patent/PL3166596T3/pl unknown
- 2015-07-06 LT LTEP15738484.3T patent/LT3166596T/lt unknown
- 2015-07-06 BR BR112016030243-5A patent/BR112016030243B1/pt active IP Right Grant
- 2015-07-06 EA EA201991359A patent/EA201991359A1/ru unknown
- 2015-07-06 PH PH1/2016/502540A patent/PH12016502540B1/en unknown
- 2015-07-06 SG SG11201610227TA patent/SG11201610227TA/en unknown
- 2015-07-06 KR KR1020177000218A patent/KR102468610B1/ko active Active
- 2015-07-06 EP EP18176177.6A patent/EP3412278A1/en not_active Withdrawn
-
2016
- 2016-12-04 IL IL249374A patent/IL249374B/en unknown
-
2017
- 2017-01-06 CL CL2017000026A patent/CL2017000026A1/es unknown
- 2017-02-10 EC ECIEPI20178187A patent/ECSP17008187A/es unknown
-
2018
- 2018-09-05 CY CY181100925T patent/CY1120749T1/el unknown
- 2018-10-30 US US16/175,082 patent/US10709691B2/en active Active
-
2019
- 2019-06-25 JP JP2019117118A patent/JP2019194221A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR134222A2 (es) | Un proceso para preparar una composición de comprimido adecuada para el tratamiento de trastornos mediados por la actividad de la tirosina cinasa de bruton | |
| AR107391A1 (es) | Formulaciones / composiciones que comprenden un inhibidor de btk | |
| CL2016001411A1 (es) | Unidad de dosificación farmacéutica solida de desintegración oral que comprende un componente de estetrol; metodo de preparación; uso para la anticoncepción femenina y en terápia de sustitución hormonal femenina. | |
| BRPI0606332A2 (pt) | composição farmacêutica de bendamustina, preparação liofilizada, forma de dosagem farmacêutica, método para obter aprovação oficial para um produto de bendamustina, processo para fabricar uma preparação liofilizada de bendamustina, solução ou dispersão de pré-liofilização de bendamustina, pó liofilizado, método para preparar uma preparação liofilizada de bendamustina, formulação para liofilização, e, uso de uma solução farmaceuticamente aceitável | |
| AR049000A1 (es) | Formulacion para compresion directa y proceso para la preparacion de una tableta directamente comprimida | |
| CU24619B1 (es) | Letermovir amorfo y formulaciones farmacéuticas sólidas del mismo para administración por via oral | |
| WO2010103544A3 (en) | A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants | |
| AR065580A1 (es) | Mejoras en composiciones medicinales o relativas a las mismas | |
| RU2013121795A (ru) | Фармацевтические композиции, содержащие ингибитор dgat1 | |
| AR100977A1 (es) | Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación | |
| PH12020551911A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| MX2024007642A (es) | Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades. | |
| RU2015109566A (ru) | НОВЫЕ ЭКСТРАКТЫ ИЗ CYNARA SCOLYMUS, COFFEA spp. И OLEA EUROPAEA ДЛЯ ЛЕЧЕНИЯ МЕТАБОЛИЧЕСКОГО СИНДРОМА | |
| PE20160183A1 (es) | FORMULACION DE LIBERACION MODIFICADA DEL ACIDO (-)-(3aR,4S,7aR)-4-HIDROXI-4m-TOLILETINIL-OCTAHIDRO-INDOL-1-CARBOXILICO (AFQ056) | |
| RU2016117186A (ru) | Комбинированная композиция, содержащая тадалафил и амлодипин | |
| AR065582A1 (es) | Mejoras en composiciones medicinales o relativas a las mismas | |
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| AR101116A1 (es) | Formas de dosificación farmacéuticas para administración oral | |
| RU2008147668A (ru) | Способ получения фармацевтических композиций посредством прессования нагреваемыми роликами | |
| MX2015008032A (es) | Una composicion farmaceutica que contiene candesartan cilexetilo y amlodipina. | |
| AR097512A1 (es) | Forma de dosis unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolítico que comprende darunavir y ritonavir | |
| CO6280494A2 (es) | Composiciones que comprenden euphorbia prostrata y procesos de preparacion de las mismas | |
| RU2015129714A (ru) | Композиция в форме таблеток, содержащая гидрохлорид цинакалцета | |
| PE20160520A1 (es) | Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion | |
| TN2016000179A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |